Boehringer Ingelheim submitted U.S., European and Canadian applications for an antidote to its own Pradaxa, leading the way among companies developing treatments that reverse the effects of blockbuster next-generation anticoagulants.
What's long been a three-horse race just gained a fourth horse with the FDA's green light for Daiichi Sankyo's clot-fighter Savaysa. With the FDA's Thursday blessing, the drug will now face down a new-age anticoagulant trifecta that's been duking it out in the marketplace for a while now.
This week, the U.K. National Institute for Health and Care Excellence blessed Pfizer's kidney cancer treatment Inlyta, changed its mind in support of Bayer's prostate cancer therapy Xofigo, and backed Boehringer Ingelheim's anticoagulant Pradaxa for blood clots in the legs and lungs.
The safety message on Boehringer Ingelheim's key product, Pradaxa, has been mixed. But the German drugmaker has rolled out some new studies that show its effectiveness, as well as some promising data about the antidote being developed to treat serious bleeding in Pradaxa patients.
One drug. Two new safety studies promoted on the same day. Two different conclusions. That's the situation with Pradaxa, the Boehringer Ingelheim anticoagulant that's drawn scrutiny for reports of serious bleeding--and prompted safety reviews in the U.S. and EU
Boehringer Ingelheim has completed a trifecta of approvals for its blood thinner Pradaxa for deep vein thrombosis and pulmonary embolism. The U.K. cost watchdog NICE has now given it a thumbs up after the FDA and the European regulators did the same thing this year.
The BMJ has set off a kerfuffle--and a Twitter campaign--over the safety of Boehringer Ingelheim's blockbuster anticoagulant Pradaxa.
German giant Boehringer Ingelheim is racing to the market with an antidote to its blockbuster blood-thinner Pradaxa, securing the FDA's coveted breakthrough therapy designation for its in-development treatment.
In keeping with the FDA's recent approval, the European Commission has green-lighted Boehringer Ingelheim's clot-fighter Pradaxa to treat and prevent the recurrence of deep vein thrombrosis and pulmonary embolism, a nod that will boost Pradaxa as it battles it out in the anticoagulant market.
Boehringer Ingelheim has agreed to pay $650 million to wrap up thousands of lawsuits claiming Pradaxa, an anticoagulant, caused serious--even fatal--bleeding in some patients. The deal comes just weeks after the FDA completed a safety review of the drug, concluding that it was as safe as the older drug it seeks to replace, warfarin.